Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Change in Account Payables (2019 - 2025)

Eton Pharmaceuticals' Change in Account Payables history spans 7 years, with the latest figure at $2.1 million for Q3 2025.

  • For Q3 2025, Change in Account Payables rose 284.42% year-over-year to $2.1 million; the TTM value through Sep 2025 reached $11.6 million, up 1129.97%, while the annual FY2024 figure was $2.3 million, 4273.58% up from the prior year.
  • Change in Account Payables for Q3 2025 was $2.1 million at Eton Pharmaceuticals, down from $7.3 million in the prior quarter.
  • Across five years, Change in Account Payables topped out at $7.3 million in Q2 2025 and bottomed at -$1.3 million in Q4 2021.
  • The 5-year median for Change in Account Payables is $105000.0 (2023), against an average of $625526.3.
  • The largest annual shift saw Change in Account Payables crashed 1033.09% in 2021 before it soared 5688.46% in 2025.
  • A 5-year view of Change in Account Payables shows it stood at -$1.3 million in 2021, then soared by 156.11% to $712000.0 in 2022, then tumbled by 85.25% to $105000.0 in 2023, then surged by 1311.43% to $1.5 million in 2024, then surged by 43.18% to $2.1 million in 2025.
  • Per Business Quant, the three most recent readings for ETON's Change in Account Payables are $2.1 million (Q3 2025), $7.3 million (Q2 2025), and $705000.0 (Q1 2025).